Stifel Nicolaus Lowers Insulet (NASDAQ:PODD) Price Target to $225.00

Insulet (NASDAQ:PODD) had its target price cut by Stifel Nicolaus from $250.00 to $225.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 40.11% from the stock’s current price.

Several other research analysts also recently issued reports on PODD. Piper Sandler lowered their price objective on Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Weiss Ratings downgraded shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. BTIG Research reduced their target price on shares of Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a report on Tuesday, May 26th. Wells Fargo & Company cut their price target on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Finally, Evercore set a $180.00 price objective on shares of Insulet in a research note on Monday. Twenty-two research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $237.08.

Insulet Stock Up 1.5%

Shares of NASDAQ:PODD opened at $160.59 on Friday. Insulet has a 52-week low of $138.79 and a 52-week high of $354.88. The company has a market capitalization of $11.12 billion, a PE ratio of 37.04, a price-to-earnings-growth ratio of 1.10 and a beta of 1.11. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The company has a fifty day moving average of $152.91 and a 200-day moving average of $211.69.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter in the previous year, the company posted $1.02 EPS. Insulet’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts predict that Insulet will post 6.46 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

A number of hedge funds and other institutional investors have recently made changes to their positions in PODD. Larson Financial Group LLC boosted its holdings in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet during the 4th quarter valued at about $26,000. Elyxium Wealth LLC purchased a new position in shares of Insulet during the 4th quarter valued at about $28,000. DV Equities LLC purchased a new position in shares of Insulet during the 4th quarter valued at about $28,000. Finally, MV Capital Management Inc. bought a new stake in Insulet in the 4th quarter worth approximately $29,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet expanded Omnipod 5 into Spain, marking its 20th country launch and broadening its international diabetes-care footprint. Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain
• Neutral Sentiment: One commentary suggested PODD may still be attractive after its sharp pullback, arguing the stock remains expensive relative to expectations but highlighting that the selloff may have created value. Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47%
• Neutral Sentiment: Another article framed PODD as a growth stock, but it was largely a general style-score commentary and did not appear to add materially new information for investors. Here’s Why Insulet (PODD) is a Strong Growth Stock
• Negative Sentiment: Multiple law firms announced or reminded investors about a pending securities fraud class action against Insulet, with deadlines to seek lead-plaintiff status, keeping legal overhang front and center. Insulet (NASDAQ:PODD) Safety Issues Trigger Securities Fraud Class Action – Investors Notified to Contact BFA Law about the Lawsuit
• Negative Sentiment: The lawsuits allege Insulet misled investors about Omnipod safety and manufacturing quality issues, including corrections affecting millions of pods, which is the main reason the stock is being pressured. Levi & Korsinsky Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 31, 2026 – PODD

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.